COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Combo Chemo, Bev &/or Atezo in Treating Patients w/Deficient DNA Mismatch Repair Metastatic CRC

To determine if treatment with mFOLFOX6/bevacizumab plus atezolizumab ) and atezolizumab is more effective than treatment with mFOLFOX6/bevacizumab alone in patients with metastatic colon cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

United States (Nationwide)

Additional Study Information

Principal Investigator

Hanna Sanoff
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Colorectal)

IRB Number

18-1438

ClinicalTrials.gov

NCT02997228

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.